51 Lakh people in India are at risk of contracting Chikungunya in the Long Term: Study

India is projected to face the most significant long-term impact of chikungunya, with an estimated 51 lakh people at risk annually, according to a global modelling study published in BMJ Global Health. Brazil and Indonesia follow as the second and third most affected countries, with India and Brazil together accounting for 48% of the global healthcare and individual burden. Researchers from the London School of Hygiene and Tropical Medicine highlight chronic health effects as the major concern, with about half of those infected potentially suffering long-term disabilities.

Globally, over 1.4 crore people could be at risk yearly, predominantly children under 10 and adults over 80. Chikungunya is transmitted by Aedes mosquitoes, causing fever, severe joint pain, and in many cases, prolonged disability. With no specific treatments, two vaccines are approved in some countries, including the US. The study emphasizes urgent public health preparedness and targeting vulnerable populations for vaccination to mitigate this growing threat.

REFERENCE: Kang H, Lim A, Auzenbergs M, Clark A, Colón-González FJ, Salje H, et al. Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study. BMJ Global Health. 2025;10:e018598. https://doi.org/10.1136/bmjgh-2024-018598

Powered by WPeMatico

15 Indian psychiatrists, doctors, scientists listed in Stanford 2025 List of World’s Top 2% Scientists

New Delhi: A total of 15 psychiatrists from India’s leading health and medical institutions have been recognised in the Stanford list of the world’s top 2% scientists. The prestigious database, curated by Professor John P.A. Ioannidis of Stanford University in collaboration with the Elsevier Data Repository, acknowledges their pioneering research, clinical excellence, and sustained impact in the field of psychiatry.

Stanford University’s database of top-cited scientists for the year 2025 provides standardised information on citations, h-index, co-authorship-adjusted h-index, citations to papers in different authorship positions, and a composite indicator (c-score). The selection is based on the top 100,000 scientists by c-score (with and without self-citations) or a 2% or above percentile rank in the sub-field.

Below are the details of Indian psychiatrists featured in Stanford University’s list for 2025:

1. Dr Chittaranjan Andrade:

Dr Chittaranjan Andrade, a Senior Professor in the Department of Clinical Psychopharmacology and Neurotoxicology at the National Institute of Mental Health and Neuro Sciences (NIMHANS) in Bengaluru, has over four decades of experience in clinical psychopharmacology, research, and education. His academic achievements began early, with 25 prizes in pre-collegiate education, 4 prizes during college, and 9 gold medals in medical school, including the Best Outgoing Student Award from his university. He stood 4th in Karnataka during his undergraduate education and topped the university in his postgraduate examinations.

Over his prolific career, Dr Andrade has authored 784 publications, with more than 216,000 reads and 14,600 citations. His primary research interests include ketamine, psychopharmacology, electroconvulsive therapy, statistics, and research methodology. In the 2024 Stanford University global database, he was ranked among the top 0.1% of scientists across 174 fields. This year, in the 2025 Stanford list, he has achieved a rank of 881 based on the composite score, excluding self-citations. By the end of 2024, Dr Chittaranjan Andrade’s h-index, excluding self-citations, stands at 16.

He plays an active role in advancing psychiatric education. He serves as Field Editor (Clinical Therapeutics) for Bipolar Disorders and sits on the editorial boards of several leading journals, including the Journal of Clinical Psychiatry, Journal of ECT, Brain Stimulation, and the Indian Journal of Psychiatry, among others. He has guided numerous postgraduate theses and is widely recognized as a dedicated mentor and educator.

In addition, he runs two major academic initiatives: Synergy Times, a thrice-weekly global e-newsletter published since 2001, and e-Journal Club India, launched in 2016 to support postgraduate psychiatry students and faculty in research methodology and academic publishing. Beyond psychiatry, Dr Andrade is a published children’s author, with three books to his name. He is also a columnist and freelance journalist, having written over 800 articles across a range of topics.

2. Dr. Debanjan Banerjee:

Dr. Debanjan Banerjee is a distinguished Consultant Geriatric Psychiatrist at Apollo Hospitals, Kolkata. His work focuses on the psychosocial impact of the COVID-19 pandemic, the psychology of misinformation, media reporting of suicides, and the marginalization of ageing populations.

His journey into psychiatry began with his MBBS from Calcutta National Medical College, followed by a gold medal for his academic excellence. Building on this foundation, he completed his M.D. in Psychiatry from NIMHANS before embarking on a post-doctoral fellowship in Geriatric Psychiatry. His passion for mental health in aging populations led him to specialise in old-age mental health, an area that remains underexplored but is crucial as the global population ages rapidly.

With 139 publications, over 56,578 reads, and 5,668 citations, Dr Banerjee has significantly contributed to the academic literature in social psychiatry and geriatrics. His research interests are wide-ranging, with a particular emphasis on social constructivist approaches, including Interpretative Phenomenological Analysis (IPA), Cognitive Grounded Theory (CGT), and Focus Group Discussions (FGD).

According to the data, he is recognized in the Stanford 2% Scientists list, holding a rank of 20,414 based on the composite score excluding self-citations, and 23,538  when all citations are included. By the end of 2024, his h-index, excluding self-citations, stands at 11, with a total of 485 citations for the year, also excluding self-citations.

He plays an active role in various community programs focused on mental health awareness, stigma reduction, and the training of general physicians. Additionally, he conducts research in social psychology. Apart from these contributions, he serves as the editor for two local magazines based in Kolkata.

3.  Dr Sandeep Grover:

Dr Sandeep Grover, a distinguished Professor of Psychiatry, is currently serving in the Department of Psychiatry at the prestigious Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh.

Dr Grover’s dedication to psychiatric education is evident through his role as a Professor at PGIMER, where he mentors postgraduate students and conducts research.

With over 1,132 publications, Dr. Grover’s research has made significant contributions to the global understanding of psychiatric disorders, their treatment, and their social impact.

He holds a rank of 22,329 in the list based on the composite score excluding self-citations. By the end of 2024, his h-index, excluding self-citations, stands at 13, with a total of 1579 citations for the year, also excluding self-citations.

4. Dr. Lakshmi Sagar Vijayakumar:

As the founder of SNEHA (Suicide Prevention Program) in Chennai, Dr. Vijayakumar has impacted countless lives through her work in the prevention of suicide, offering support to individuals in crisis, and raising awareness about mental health challenges.

She also serves as the Head of the Department of Psychiatry at Voluntary Health Services in Adyar, Chennai. An active member of the World Health Organization’s International Network for Suicide Research and Prevention, Dr. Vijayakumar is an Honorary Associate Professor at the University of Melbourne, Australia.

Previously, she served as the Vice President of the International Association for Suicide Prevention (IASP) for four years and received the prestigious Ringel Service Award for her contributions. She has been honoured with the Honorary Fellowship of the Royal College of Psychiatrists (FRCPsych) in the UK and the Fellowship of the Royal College of Physicians of Edinburgh (FRCP EDIN) for her extensive work on suicide prevention.

Her pioneering work has gained global recognition. In 2014, Dr. Vijayakumar was a co-editor of the WHO’s report titled “Preventing Suicide — A Global Imperative.”

She has published extensively in peer-reviewed journals, authored numerous book chapters, and edited two books on the subject. In India, she has received several prestigious awards, including the ‘For The Sake of Honour’ Award, Bharathi Virudu, and the Women Doctor of the Year Award. She has been a tireless advocate for the decriminalization of suicide, the establishment of media guidelines for reporting suicide, and the development of a national suicide prevention strategy for India.

According to the Stanford 2% Scientist list, he holds a rank of 23,506. By the end of 2024, his h-index, excluding self-citations, stands at 18.

5. Dr Ravi Philip Rajkumar:

Dr Ravi Philip Rajkumar, currently working as a Professor of Psychiatry at JIPMER (Jawaharlal Institute of Postgraduate Medical Education and Research) in Pondicherry, is renowned for his work in the areas of psychopharmacology, neuropsychiatry, and psychosomatic disorders.

Dr. Rajkumar holds an M.B.B.S. and M.D. in Psychiatry, qualifications that have laid a solid foundation for his career in both medicine and psychiatry. As a professor, he plays an active role in educating the next generation of psychiatrists and mental health professionals.

He has been recognized as one of the top 2% scientists worldwide, according to Stanford University’s list for 2025, where he holds the rank of 29,405.

6. Dr Sujita Kumar Kar

Dr. Sujita Kumar Kar is an academic researcher currently based at King George’s Medical University (KGMU) in Lucknow, where he contributes significantly to the field of psychiatry and neuropsychiatry.

Dr. Kar completed his MBBS from MKCG Medical College, Berhampur, in 2004 and went on to pursue advanced research and clinical work in psychiatry. He has authored 361 research papers and has been cited 584 times for his work, making notable contributions in areas such as mood disorders, psychosis, and biological psychiatry. His research interests primarily focus on non-invasive brain stimulation (neuromodulation).

In 2025, he is recognized as one of the top 2% of scientists globally according to Stanford’s list, with a rank of 45,404. By the end of 2024, his h-index, excluding self-citations, stands at 13, with a total of 40,546 citations for the year, also excluding self-citations.

7. Dr. Kuruthukulangara Sebastian

Dr. Kuruthukulangara Sebastian Jacob is an esteemed academic and researcher, currently affiliated with the University of Melbourne, Melbourne, Australia.

Dr. Jacob has an extensive publication record with 8,665 citations drawn from 6,820 documents. He has authored 255 research papers and boasts a notable h-index of 52. Additionally, he has one preprint and has collaborated with 421 co-authors over the course of his career.

Notably, he is ranked in Stanford University’s list of top 2% scientists worldwide for 2025, with an impressive rank of 52,559.

His research interests span a variety of topics, including DSM-IV, the sleep-waking cycle, overactive bladder, urolithiasis, and chronic obstructive pulmonary disease (COPD). He is also focused on evidence-based medicine, radiology, and community mental health. Additionally, his work includes exploring neuroticism, the International Classification of Diseases (ICD-10), and the role of hydrocortisone in various medical conditions.

8. Dr Om Prakash Singh:

Dr. Om Prakash Singh, a distinguished psychiatrist, currently serves as a professor at Midnapore Medical College. Previously, he held prestigious positions, including Professor of Psychiatry at IPGMER and SSKM Hospital, as well as Assistant Professor at Burdwan Medical College, where he later became Professor and Head of the Psychiatry Department.

Dr. Singh’s academic journey began with his studies at Scottish Church College, Calcutta, followed by his medical training at Lady Hardinge Medical College and later at Burdwan Medical College and Hospital. With his vast experience and expertise, Dr. Singh has contributed significantly to both clinical psychiatry and medical education.

He has been recognised as one of the top 2% scientists across the world, as per Stanford University’s list of 2025. According to the data, Dr. Om Prakash Singh holds a rank of 62,399 in the list. By the end of 2024, his h-index, excluding self-citations, stands at 8.

9. Dr. Santosh Kumar Chaturvedi

Dr. Santosh Kumar Chaturvedi is a renowned figure in the field of psychiatry and behavioural sciences, holding the prestigious position of Former Dean, Behavioural Sciences and Professor of Psychiatry at the National Institute of Mental Health & Neurosciences (NIMHANS) in Bangalore.

Dr. Chaturvedi’s academic journey began at Maulana Azad Medical College, where he earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree. His passion for understanding the human mind and mental health led him to pursue further specialization in psychiatry, earning a Doctor of Medicine (MD) in Psychiatry from the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh between 1979 and 1982.

He is a member of both the International Psycho-Oncology Society and the Indian Association of Palliative Care. He has also served as a member of the Board of Directors for the International Psycho-Oncology Society.

In addition to his academic and clinical roles, Dr. Singh regularly conducts workshops on Communication Skills in Oncology and Palliative Care settings and trains trainers to teach these essential skills. His areas of expertise include consultation-liaison psychiatry, chronic pain management, psychosocial oncology, palliative care, and quality of life research.

10. Dr. Ajit K. Avasthi

Dr. Ajit K. Avasthi is a renowned psychiatrist and expert in the fields of schizophrenia, affective disorders, and psychosexual dysfunctions. He is currently affiliated with the Postgraduate Institute of Medical Education and Research (PGIMER) in Chandigarh. He also serves as a Consultant in Mental Health and Behavioural Sciences at Fortis Hospital, Mohali.

He has earned prestigious accolades over the years. These include the PPA-I Award in 2005, presented by the Indian Psychiatric Society for his Best Published Paper, followed by the same recognition in 2008 for another outstanding paper. Additionally, he received the Dr. Buckshey Award in 2011 during the XXXVIth North Zonal Conference of the Indian Psychiatric Society.

Dr. Avasthi’s primary areas of expertise encompass a range of mental health conditions, including schizophrenia, affective disorders such as depression and bipolar disorder, and psychosexual dysfunctions. His extensive knowledge and experience in these areas contribute to his reputation as a leading figure in the field of psychiatry.

He has been recognised as one of the top 2% scientists globally according to Stanford University’s 2025 list based on the composite score, excluding self-citations. He has an impressive rank of 71,272 in the list. 

11. Dr Gururaj Gopalkrishna

Dr. Gururaj Gopalkrishna, with an extensive background as a Senior Professor and Director at the National Institute of Mental Health and Neuro Sciences (NIMHANS), currently serves as an Advisor and Consultant in the fields of Public Health, Road Safety, and Mental Health.

In recognition of his exceptional contributions to the field, Dr. Gopalkrishna has been acknowledged in Stanford University’s 2% Scientists list for 2025. The data in the list shows that Dr. Gururaj Gopalkrishna Vaid holds a rank of 93,473 in the list based on the composite score excluding self-citations, and 92840 when all citations are included. By the end of 2024, Dr. Malhotra’s h-index, excluding self-citations, stands at 13, with a total of 1,169 citations for 2024 (excluding self-citations).

12. Dr. Vikas Menon

After pursuing his MBBS at JIPMER, Puducherry, Dr. Vikas Menon specialised further in psychiatry by completing his MD in Psychiatry from JIPMER and obtaining a DNB Psychiatry from the National Board of Examinations, New Delhi.

He is currently serving as a Professor of Psychiatry at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry.

Dr. Menon’s primary research interests revolve around mood disorders, suicide prevention, and digital psychiatry. He is particularly passionate about addressing the treatment gap in psychiatry, particularly through the use of innovative and frugal technologies that can make mental health care more accessible to underserved populations.

Dr. Menon has contributed significantly to academic literature, with 426 publications and over 132,000 reads and 7,026 citations to his name. His work is also recognized globally, earning him a spot in Stanford University’s 2% list of the world’s top scientists, with a ranking of 94,207. According to the list, by the end of 2024, his h-index, excluding self-citations, stands at 11.

13. Dr Telkar Srinivas Sathyanarayana Rao

Dr. Telkar Srinivas Sathyanarayana Rao currently works at the JSS Academy of Higher Education & Research in the Department of Psychiatry, where he serves as a prominent faculty member.

He has built a notable academic career after completing his B.Sc. from Sahyadri College.

His significant contributions to the field of psychiatry have earned him global recognition, and he has been ranked among the top 2% of scientists worldwide, according to Stanford University’s 2025 list, with a rank of 100,573.

His research interests encompass a broad range of topics, including oxidative stress, bipolar I disorder, hypomania, and the impact of mental disorders such as Alzheimer’s disease. He has also contributed to studies on the Coronavirinae family, COVID-19, the hippocampus, and the implications of social distancing.

14. Dr. Rakesh K. Chadda

Dr. Rakesh K. Chadda stands as one of India’s most distinguished psychiatrists, with over four decades of dedicated service to the field of mental health. He is currently serving as the Head of the Department of Psychiatry at Amrita Hospital.

Dr. Chadda has held several prominent positions across India’s most esteemed medical institutions. He served as Professor and Head of the Department of Psychiatry, as well as Chief of the National Drug Dependence Treatment Centre at the All India Institute of Medical Sciences (AIIMS), New Delhi. Earlier in his career, he contributed as Professor of Psychiatry at the Institute of Human Behaviour and Allied Sciences (IHBAS), Delhi, and also led the Department of Psychiatry at UCMS & GTB Hospital, Delhi.

On the international front, Dr. Chadda worked as a Consultant Psychiatrist in the National Health Service (NHS), United Kingdom, during 2004–05

He currently serves as President-Elect of the World Association of Social Psychiatry (WASP) for the 2022–25 term, having previously held the role of Secretary General (2019–22).

Dr. Chadda’s distinguished contributions to the field of psychiatry have been recognized globally through numerous prestigious honors and fellowships. He is a Fellow of the Royal College of Psychiatrists (UK) and a Distinguished International Fellow of the American Psychiatric Association, reflecting his international standing in mental health. He has also been named an Honorary Fellow of the World Association of Social Psychiatry (WASP) and an Honorary Member of the World Psychiatric Association (WPA)—testaments to his influence on global psychiatric practice and policy. In India, his achievements have been acknowledged with a Fellowship of the National Academy of Medical Sciences (NAMS).

His scholarly works have been published in prestigious journals like The British Journal of Psychiatry, American Journal of Psychiatry, The Lancet, Acta Psychiatrica Scandinavica, Psychiatric Research, and BJPsych International.

In recognition of his outstanding academic and research achievements, Dr. Chadda has been ranked among the top 2% of scientists globally, according to Stanford University’s 2025 list with 107,346 based on the composite score, excluding self-citations. By the end of 2024, Dr. Chadda’s h-index, excluding self-citations, stands at 8.

15. Dr. Shilpa Aggarwal

Dr. Shilpa Aggarwal, currently serving at SRCC Children’s Hospital, is a renowned Mental Health and Behavioural Sciences Specialist with over 10 years of clinical experience in the field of psychiatry. She holds extensive qualifications, including MBBS, MD in Medicine, DNB in Psychiatry from KEM Hospital, Mumbai, and advanced training in Child and Adolescent Psychiatry. She is also a Fellow of the Royal Australian and New Zealand College of Psychiatrists.

Her primary focus is evidence-based mental health care tailored to the unique needs of each patient. Dr. Aggarwal’s specialized knowledge in child and adolescent psychiatry allows her to effectively address a wide range of developmental, emotional, and behavioral challenges that affect younger populations.

She is a respected figure in the field, with 1,020 citations and an h-index of 16. Dr. Aggarwal’s inclusion in Stanford University’s list of the top 2% scientists worldwide for 2025. According to the data, it has achieved a rank of 107,667 based on the composite score, excluding self-citations. By the end of 2024, Dr. Shilpa Aggarwal’s h-index, excluding self-citations, stands at 8.

Powered by WPeMatico

Health Bulletin 04/October/2025

Here are the top health stories of the day:

Attacks on doctors threaten Lives and patient safety in Hospitals: Delhi HC Warns

While considering a criminal case against a patient’s attendant who had allegedly assaulted a doctor, the Delhi High Court bench took note of the compromise entered into between the parties and held that such an act of assault upon a medical professional, apart from endangering the lives of doctors and staff, also jeopardises the treatment of other patients needing urgent care.

“…this Court cannot lose sight of the fact that an act of assault upon a medical professional in a hospital not only endangers the life of doctors and staff, but also jeopardises the treatment of other patients in need of urgent care,” observed the High Court bench.

Even though the court quashed the criminal case against the accused (the patient’s attendant in question), it asked him to perform community service for a month.

For more details, check out the full story on the link mentioned below:

Assault upon medical professionals in hospitals endangers doctors’ lives, jeopardises patient care: Delhi HC

NMC Sets Deadline for Medical Colleges to submit NEET SS 2024 Admission details online

The Post Graduate Medical Education Board (PGMEB) has directed all medical colleges to submit information relating to admission made in Medical College/Postgraduate Institute through the National Eligibility and Entrance Test-Super Speciality (NEET SS) for the academic year 2024.

Through the letter, the Medical Colleges are required to ensure that all admissions in the SS courses are strictly in accordance with merit and are made transparently and fairly as envisaged in the Regulations. Any violation shall lead to the discharge of the concerned students from the courses and such action against the concerned Medical College/Institution as is permissible in law.

For more details, check out the full story on the link mentioned below:

NMC deadline to medical colleges to submit NEET SS 2024 admission details online


Punjab and Haryana HC criticises doctors over Illegible prescriptions

Slamming doctors for continuing to write illegible prescriptions despite access to computers, the Punjab and Haryana High Court has directed them to write in clear, bold capital letters until a comprehensive digital prescription system is established.

The court emphasised that patients have a fundamental right to receive clear and readable medical prescriptions, stressing that poor handwriting can directly impact a patient’s health and safety.

To prevent confusion, the court instructed the government to introduce handwriting training in medical curricula and to implement a nationwide digital system within two years. Until then, it directed doctors to write in bold, legible letters.

For more details, check out the full story on the link mentioned below:

Illegible Prescriptions Not Acceptable: Punjab and Haryana HC raps doctors


51 Lakh people in India are at risk of contracting Chikungunya in the Long Term: Study

India is projected to face the most significant long-term impact of chikungunya, with an estimated 51 lakh people at risk annually, according to a global modelling study published in BMJ Global Health. Brazil and Indonesia follow as the second and third most affected countries, with India and Brazil together accounting for 48% of the global healthcare and individual burden. Researchers from the London School of Hygiene and Tropical Medicine highlight chronic health effects as the major concern, with about half of those infected potentially suffering long-term disabilities.

Globally, over 1.4 crore people could be at risk yearly, predominantly children under 10 and adults over 80. Chikungunya is transmitted by Aedes mosquitoes, causing fever, severe joint pain, and in many cases, prolonged disability. With no specific treatments, two vaccines are approved in some countries, including the US. The study emphasises urgent public health preparedness and targeting vulnerable populations for vaccination to mitigate this growing threat.

REFERENCE: Kang H, Lim A, Auzenbergs M, Clark A, Colón-González FJ, Salje H, et al. Global, regional and national burden of chikungunya: force of infection mapping and spatial modelling study. BMJ Global Health. 2025;10:e018598. https://doi.org/10.1136/bmjgh-2024-018598

Powered by WPeMatico

CDSCO Flags MSD Pharma’s Cancer Drug Trial Over Indian Representation, Control Arm

New Delhi: The Subject Expert Committee (SEC) on Oncology under the Central Drugs Standard Control Organization (CDSCO) has raised critical concerns over the Phase III clinical trial proposal of Sacituzumab Tirumotecan submitted by MSD Pharmaceuticals Pvt. Ltd., directing the company to provide detailed justifications regarding its study design and patient representation in India.

MSD Pharmaceuticals Pvt. Ltd., the Indian subsidiary of global biopharmaceutical company Merck & Co., presented its Phase III clinical trial Protocol No. MK2870-032, Version 00, dated February 18, 2025, for evaluation.

Sacituzumab Tirumotecan is an investigational antibody-drug conjugate (ADC) being developed for the treatment of various cancers, including triple-negative breast cancer and metastatic urothelial carcinoma. The drug combines a humanized monoclonal antibody targeting the Trop-2 receptor with a cytotoxic topoisomerase I inhibitor payload, enabling selective delivery of chemotherapy directly to tumor cells while minimizing systemic toxicity.

During the SEC review, the committee identified two significant issues. Firstly, the proposed control arm in the study was not aligned with the current standard of care, prompting the SEC to ask the company for a clear scientific rationale behind its selection. Secondly, the committee noted that the proposed inclusion of only 60 Indian patients – representing less than 3% of the global trial population of 2,400—was inadequate to generate statistically meaningful outcomes for the Indian population.

The SEC emphasized that such limited representation could compromise the reliability and applicability of trial results in India, potentially affecting regulatory evaluation and future patient access. In light of this, the committee requested MSD Pharmaceuticals to substantially increase the Indian sample size to ensure appropriate representation and robust statistical validity.

After detailed deliberation, the SEC directed the company to submit comprehensive justifications regarding the control arm choice and provide a revised study plan with an expanded Indian cohort. The committee clarified that the trial cannot proceed for further consideration until these issues are adequately addressed, reinforcing the importance of robust trial design and sufficient patient representation for global oncology studies conducted in India.

Powered by WPeMatico

Pharmacist Suspended, New Dispensing Guidelines Issued in Rajasthan Amid Cough Syrup Row

Jaipur: The cough syrup controversy in Rajasthan has now led to suspensions and sweeping new guidelines, as the health department cracked down on lapses following the deaths of children allegedly linked to dextromethorphan hydrobromide syrup. The state government suspended a pharmacist and a doctor of Hathideh PHC in Ajitgarh block, Sikar, for allegedly prescribing the syrup to a child, despite the drug not being recommended for children under four.

According to a recent media report in the Times of India, Director of Public Health Dr Ravi Prakash Sharma confirmed the disciplinary action and announced fresh directives for medical staff. The guidelines stress that no medicine can be dispensed without a valid prescription, and doctors must refrain from prescribing dextromethorphan syrups to children. Patients too have been warned against self-medication, with officials highlighting that unregulated use of the syrup can be dangerous.

The controversy escalated after multiple cases were reported across Rajasthan. While fatalities in Sikar and Bharatpur drew attention, the health department clarified that not all cases resulted in death. In one instance, three-year-old Gagan, son of Monu Joshi from Bharatpur, developed cough and fever and was given the syrup by his father without prescription. He later fell ill but recovered after hospital treatment and was discharged, underscoring the risks of unsupervised use, reports Times of India

Powered by WPeMatico

Orthopaedic Surgeon accused of exploiting woman over marriage promise

Thane: An orthopaedic surgeon from Ambernath has been accused of sexual exploitation by a woman. The woman, whose husband was earlier treated by the doctor, alleged that he took advantage of her following her husband’s death. 

Alleging the doctor sexually assaulted her under the pretext of marriage, the widow filed a complaint against the doctor, and accordingly, he is booked under relevant sections of BNS. 

Also read- Doctor gets bail in alleged sexual assault of 17-year-old boy

According to the complainant, the doctor approached her and promised to marry her. She claimed that he believed him and therefore entered into a relationship with him. They had repeated sexual interactions, as per the TOI media report. 

The situation took a turn when the complainant alleged that she realised that the doctor had deceived her. Following this, she approached the police and filed a complaint against the doctor. 

Based on her statement, the police registered an FIR, and further investigation is underway.

Medical Dialogues recently reported that a gynaecologist posted at the sub-district hospital in Banihal, Jammu and Kashmir’s Ramban district, was arrested by the police following allegations of misconduct involving a female patient. The incident took place when a female patient levelled allegations of misconduct against a consultant gynaecologist at the sub-district hospital, Banihal, triggering anger among people in the area. 

Also read- Banihal Gynaecologist suspended over alleged misconduct with patient

Powered by WPeMatico

DoP Notifies Rs 5000 Cr PRIP Scheme to Boost Pharma, MedTech R&D

New Delhi: The Department of Pharmaceuticals (DoP) has notified major amendments to the Scheme for Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) through a recent Gazette notification, with a massive financial outlay of Rs 5000 crore from FY 2023-24 to FY 2029-30.

The scheme aims to transform India’s pharma and MedTech sector from cost-driven to innovation-led growth, build robust research infrastructure, foster global collaborations, and accelerate commercialization of indigenous technologies.

The scheme operates through two components.

Under Component A, seven Centres of Excellence (CoEs) will be set up at NIPERs in Mohali, Ahmedabad, Hyderabad, Guwahati, Kolkata, Hajipur, and Raebareli, with a budget of ₹700 crore. Each CoE will specialize in priority areas such as anti-viral/anti-bacterial drug discovery, medical devices, bulk drugs, flow chemistry, novel drug delivery systems, phytopharmaceuticals, and biological therapeutics.

Component B provides direct financial assistance to startups, MSMEs and industry for both early-stage and late-stage R&D projects. Early-stage projects can receive up to ₹5 crore (without co-funding if the project cost ≤₹1 crore), while late-stage projects may avail up to ₹100 crore with a cap of 35% central funding. For Strategic Priority Innovations addressing critical public health issues like orphan drugs or antimicrobial resistance, assistance may extend up to 50%. The notification details strong emphasis on industry–academia collaboration, encouraging joint projects with reputed government research institutions. Nine slots each are reserved for early and late-stage projects undertaken in partnership with such institutions.

The scheme also promotes intellectual property licensing, incubation, mentorship, and partnerships across startups, investors, academia, NGOs, and government bodies through dedicated online platforms. Funding disbursement will be milestone-linked, with mandatory financial closure proofs and co-funding where applicable.

Beneficiaries will also be bound by structured profit-sharing mechanisms, offering options of fixed-rate payments, graded royalty, or equity dilution in proportion to government support, ensuring accountability and reinvestment in public research. Identifying six priority R&D domains, the scheme covers new drugs (including NCEs, biologics, precision medicines, and phytopharmaceuticals), complex generics, biosimilars, cell and gene therapies, high-value patented/near-expiry drugs, and advanced medical devices such as robotic surgical tools, AI/ML-based diagnostics, telemedicine equipment, and biomarker-driven precision devices.

With a ₹4200 crore allocation under Component B alone, the scheme positions India to raise its share in the global pharma market from the present 3.4% to 5% by 2030, translating into a $160 billion industry.

Officials stressed that the reforms align with the ‘One Health’ vision, with spillover benefits for both human and animal health sectors.

Senior Economic Adviser Awadhesh Kumar Choudhary noted that the initiative represents “a decisive step to build a self-reliant and globally competitive Pharma-MedTech ecosystem blending public investment, academic excellence, and private innovation.”

To view the official Gazette, click on the link below:

Powered by WPeMatico

GLP-1RAs Show Promise for Kidney Protection in Type 2 Diabetes, Reveals Research

Italy: A new review published in Minerva Medica has revealed that GLP-1 receptor agonists may help preserve kidney function in people with type 2 diabetes.

Researchers led by Alessandro Perencin from the Department of Medicine (DIMED), Geriatrics Division, University of Padua, Italy, conducted a systematic review to examine whether this class of diabetes medications could provide direct kidney benefits. GLP-1 receptor agonists (GLP-1RAs) are already widely prescribed for blood sugar management and cardiovascular protection, but their potential to safeguard kidney health has not been comprehensively evaluated until now.
To assess this possibility, the team performed an extensive search of medical literature across databases such as PubMed, Embase, Web of Science, and the Cochrane Library. They looked for studies that reported kidney-related outcomes—specifically estimated glomerular filtration rate (eGFR), a key measure of kidney function, and albumin-to-creatinine ratio (ACR), an indicator of protein leakage in the urine—in adults with type 2 diabetes who were treated with GLP-1RAs. Each study was carefully reviewed for quality and risk of bias to ensure reliable conclusions.
Thirteen studies, including both randomized clinical trials and observational analyses, met the inclusion criteria. These investigations suggest that GLP-1RAs may slow the progression of kidney damage, reduce proteinuria, and improve other important markers of renal health in patients with diabetes. Several studies showed significant slowing of eGFR decline and reductions in ACR, pointing to a possible protective effect against diabetic kidney disease.
However, the evidence was not entirely consistent. While some studies demonstrated clear and measurable benefits, others reported only modest improvements or no significant impact on kidney function. Differences in study design, patient populations, and treatment duration may partly explain these mixed results.
Despite these variations, the authors underscore that the overall trend is encouraging. With diabetic kidney disease remaining a major cause of chronic kidney failure worldwide, therapies that can both control blood glucose and support kidney health are urgently needed. GLP-1RAs—already known to lower cardiovascular risk—could offer an added advantage by helping to preserve renal function over time.
The review calls for larger, well-structured clinical trials to confirm these preliminary findings and to clarify how GLP-1RAs exert potential nephroprotective effects. Establishing clear evidence could help physicians decide when and how to incorporate these drugs into treatment plans for people with type 2 diabetes who are at risk of kidney complications.
“The systematic review highlights the emerging role of GLP-1 receptor agonists as more than just blood sugar–lowering agents. While further research is necessary, these medications may one day become a cornerstone not only in managing type 2 diabetes and cardiovascular disease but also in protecting long-term kidney health,” the authors concluded.
Reference:
Perencin A, Ceolin C, Papa MV, Di Marzio B, Zanforlini BM, Devita M, et al. Glucagon-like peptide-1 receptor agonists and its possible nephroprotective role: a systematic review. Minerva Med 2025 Sep 11. DOI: 10.23736/S0026-4806.25.09709-5

Powered by WPeMatico

GLP-1 Receptor Agonists Show Gastrointestinal Safety with Some Risks: Study

USA: Researchers have found in a retrospective study that GLP-1 receptor agonists (RAs) are generally safe for the gastrointestinal (GI) and hepatobiliary systems in patients with type 2 diabetes (T2D).    

The study published in the American Journal of Gastroenterology revealed that the therapy was linked to lower risks of several GI cancers and complications compared with other oral antidiabetic drugs. However, GLP-1 RAs were associated with a higher risk of gastroparesis and intussusception, highlighting the need for careful monitoring in vulnerable patients.
The study, led by Dr. Chengu Niu from the Department of Internal Medicine, Rochester General Hospital, USA, analyzed electronic health records of adults with T2D treated across the United States between 2010 and 2020. Using data from the TriNetX network, researchers conducted a retrospective cohort analysis and included 230,415 patients receiving GLP-1 RAs, matched 1:1 with an equal number of patients on other oral antidiabetic medications such as metformin, empagliflozin, and sitagliptin.
Over a five-year follow-up, the study evaluated various GI and hepatobiliary outcomes, including gastroparesis, bowel obstruction, pancreatitis, cholecystitis, and related GI cancers.
The analysis revealed the following findings:
  • GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591).
  • GLP-1 RA use was associated with a higher risk of intussusception (HR 1.383).
  • GLP-1 RA therapy was linked to 15%–26% lower risks of cholangitis, bowel obstruction, ileus, volvulus, chronic pancreatitis, and procedures such as endoscopic retrograde cholangiopancreatography compared to other oral antidiabetic drugs.
  • GLP-1 RA users had lower risks of pancreatic cancer (HR 0.897), gastric cancer (HR 0.838), esophageal cancer (HR 0.741), and colorectal cancer (HR 0.870).
  • There were no significant differences in the risk of biliary cancer or hepatocellular carcinoma between GLP-1 RA users and other oral antidiabetic drug users.
  • Rates of acute pancreatitis, cholecystitis, and cholecystectomy were similar between GLP-1 RA users and the control group.
  • Overall, these findings support the gastrointestinal and hepatobiliary safety of GLP-1 receptor agonists.
The findings suggest that for patients at risk of common GI malignancies or conditions such as cholangitis and bowel obstruction, GLP-1 RAs remain a viable and generally safe option. However, clinicians are advised to exercise caution in patients with preexisting gastroparesis or intussusception, who may benefit from traditional oral antidiabetic therapies instead.
The authors noted several limitations of the study. The results show associations rather than causation, and the five-year follow-up period may not fully capture long-term cancer risks. Socioeconomic factors, access to healthcare, treatment adherence, and medication switching were not assessed and could have influenced outcomes.
“The large real-world analysis supports the gastrointestinal and hepatobiliary safety of GLP-1 receptor agonists in patients with type 2 diabetes, while highlighting the need for vigilance regarding specific complications such as gastroparesis and intussusception. Further long-term studies are needed to confirm these findings and to better assess potential cancer risks associated with GLP-1 RA therapy,” the authors concluded.
Reference:
Niu, Chengu MD1,a; Sun, Kefang MD1; Zhang, Jing MD2; Elkhapery, Ahmed MD1; Zhu, Kaiwen MD1; Malik, Sheza MD1; Xue, Chao MD1; Okolo, Patrick I MD3. Gastrointestinal and Hepatobiliary Safety of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes. The American Journal of Gastroenterology ():10.14309/ajg.0000000000003760, September 03, 2025. | DOI: 10.14309/ajg.0000000000003760

Powered by WPeMatico

Continuing ACE Inhibitors and ARBs Before Non-Cardiac Surgery Linked to Lower Postoperative Mortality and Functional Decline: Study

Continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers before non-cardiac surgery is linked to a reduced risk of postoperative mortality and functional decline, according to researchers from Science Tokyo. Using a Japanese nationwide registry of 2.6 million patients over 50 years old, the researchers compared outcomes between those who continued antihypertensive therapy and those who did not. Their findings highlight potential benefits of specific classes of antihypertensive drugs depending on type of surgery needed.

Hypertension, or high blood pressure, affects nearly 1.3 billion people globally and is a leading risk factor for serious health issues. When patients with this condition need to undergo surgery, doctors must decide on how to handle their daily blood pressure medication. This is a critical choice, given that the wrong call can lead to severe complications and a decline in the patient’s physical function after the operation.

Unfortunately, this challenge is made even more difficult due to an ongoing debate in the medical community about two main classes of antihypertensive drugs: angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs). Some doctors hold that continuing these medications can lead to a dangerous drop in blood pressure during surgery. Others have argued that stopping them may instead trigger a dangerous spike in blood pressure, which can damage multiple organs. This lack of consensus creates a clinical dilemma for doctors and puts patients at risk.

In a recent study, a research team led by Associate Professor Shintaro Mandai along with second year MD-PhD student Rena Suzukawa and Professor Shinichi Uchida from the Department of Nephrology at the Graduate School of Medical and Dental Sciences, Institute of Science Tokyo (Science Tokyo), Japan, sought to settle this issue. The study was conducted in collaboration with Professor Kiyohide Fushimi from the Department of Health Policy and Informatics, Science Tokyo. Their paper, which was published in Volume 5, Issue 4 of the European Heart Journal Open on August 11, 2025, explored the association between six classes of antihypertensive drugs and postoperative outcomes in patients undergoing non-cardiac surgeries.

Using a large nationwide registry of patient claims in Japan, the team analyzed data from approximately 2.6 million patients aged 50 years or older. They compared outcomes between patients who continued their antihypertensive therapy before and after surgery and those who did not. They also analyzed the outcomes for different combinations of drugs and whether the type of surgery was a meaningful factor.

Through comprehensive statistical analyses, the researchers revealed that patients who continued taking ACEis or ARBs had a significantly lower risk of mortality and functional decline after non-cardiac surgeries. Interestingly, these benefits were most evident among patients who underwent orthopedic or gastrointestinal surgeries, where they were also associated with a lower risk of sepsis.

These results have important clinical implications as Mandai explains, “By demonstrating the benefits of ACEis and ARBs in an area where randomized controlled trials are difficult to conduct, this study suggests the potential for preventing postoperative complications and maintaining quality of life in older adults.” The general findings contribute to ongoing discussions about perioperative antihypertensive management and suggest that continuing ACE inhibitors and ARBs, rather than withholding them as some clinicians advocate, may be linked to better postoperative outcomes.

Moreover, the study underscores a broader point about the untapped potential of common medications. “Although essential medications such as antihypertensive drugs are often discussed in the context of negative aspects like polypharmacy, this work hints at their added clinical value,” says Mandai. By focusing on these beneficial off-target effects, this research provides a new perspective on inpatient care.

Overall, these efforts by Mandai and his team will hopefully pave the way for practical guidelines for doctors managing patients with hypertension, helping them improve surgical outcomes worldwide.

Reference:

Rena Suzukawa, Shintaro Mandai, Yuta Nakano, Shunsuke Inaba, Hisazumi Matsuki, Yutaro Mori, Fumiaki Ando, Takayasu Mori, Koichiro Susa, Soichiro Iimori, Shotaro Naito, Eisei Sohara, Tatemitsu Rai, Kiyohide Fushimi, Shinichi Uchida, Perioperative antihypertensive medications and effects on functional decline and mortality in non-cardiac surgery, European Heart Journal Open, Volume 5, Issue 4, July 2025, oeaf096, https://doi.org/10.1093/ehjopen/oeaf096

Powered by WPeMatico